HUE056265T2 - Igmezin Alzheimer-kór kezelésében történõ alkalmazásra - Google Patents
Igmezin Alzheimer-kór kezelésében történõ alkalmazásraInfo
- Publication number
- HUE056265T2 HUE056265T2 HUE17704271A HUE17704271A HUE056265T2 HU E056265 T2 HUE056265 T2 HU E056265T2 HU E17704271 A HUE17704271 A HU E17704271A HU E17704271 A HUE17704271 A HU E17704271A HU E056265 T2 HUE056265 T2 HU E056265T2
- Authority
- HU
- Hungary
- Prior art keywords
- igmesine
- alzheimer
- disease
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662293832P | 2016-02-11 | 2016-02-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE056265T2 true HUE056265T2 (hu) | 2022-02-28 |
Family
ID=58009847
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE17704271A HUE056265T2 (hu) | 2016-02-11 | 2017-02-10 | Igmezin Alzheimer-kór kezelésében történõ alkalmazásra |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US11129801B2 (hu) |
| EP (2) | EP3413870B1 (hu) |
| JP (1) | JP7059192B2 (hu) |
| CN (1) | CN109069414B (hu) |
| AU (1) | AU2017218592B2 (hu) |
| CA (1) | CA3012415C (hu) |
| CY (1) | CY1124821T1 (hu) |
| DK (1) | DK3413870T3 (hu) |
| ES (1) | ES2895957T3 (hu) |
| HR (1) | HRP20211661T1 (hu) |
| HU (1) | HUE056265T2 (hu) |
| LT (1) | LT3413870T (hu) |
| PL (1) | PL3413870T3 (hu) |
| PT (1) | PT3413870T (hu) |
| RS (1) | RS62615B1 (hu) |
| SI (1) | SI3413870T1 (hu) |
| WO (1) | WO2017137600A1 (hu) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS62615B1 (sr) | 2016-02-11 | 2021-12-31 | Sigmathera Sas | Igmezin za upotrebu u lečenju alchajmerove bolesti |
| WO2023041713A1 (en) * | 2021-09-20 | 2023-03-23 | Esteve Pharmaceuticals, S.A. | Oxadiazaspiro compounds for use in the treatment of motoneuron degeneration or in neuroprotection |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4607824A (en) | 1983-01-11 | 1986-08-26 | Energy Absorption Systems, Inc. | Guardrail end terminal |
| FR2636625B1 (fr) | 1988-09-01 | 1990-11-09 | Jouveinal Sa | Benzylamines disubstituees, leur procede de preparation, leur utilisation comme medicament et leurs intermediaires de synthese |
| NZ243065A (en) | 1991-06-13 | 1995-07-26 | Lundbeck & Co As H | Piperidine derivatives and pharmaceutical compositions |
| JP4600610B2 (ja) * | 1996-05-15 | 2010-12-15 | 株式会社フジモト・コーポレーション | アセチルコリン系神経伝達改善剤 |
| AU2180400A (en) | 1999-01-13 | 2000-08-01 | Eli Lilly And Company | A pharmaceutical combination for the treatment of depression |
| EP1078630A1 (en) | 1999-08-27 | 2001-02-28 | Warner-Lambert Company | Use of sigma receptor agonists for the treatment of depression |
| US6436938B1 (en) | 2001-01-22 | 2002-08-20 | Pfizer Inc. | Combination treatment for depression |
| US20030013699A1 (en) * | 2001-05-25 | 2003-01-16 | Davis Harry R. | Methods for treating alzheimer's disease and/or regulating levels of amyloid beta peptides in a subject |
| WO2005000294A1 (en) | 2003-06-06 | 2005-01-06 | Pharmacia Corporation | Selective inhibitor and an anticonvulsant agent for the treatment of central nervous system disorders |
| US20050032827A1 (en) | 2003-06-12 | 2005-02-10 | Donna Oksenberg | Sigma ligands for neuronal regeneration and functional recovery |
| CN100420483C (zh) * | 2003-06-12 | 2008-09-24 | 株式会社爱慕知科学 | 用于神经元再生和功能恢复的σ配体 |
| KR20060133008A (ko) * | 2004-04-14 | 2006-12-22 | 워너-램버트 캄파니 엘엘씨 | 알츠하이머병을 치료하기 위한 치료용 조합물 |
| CA2607598A1 (en) * | 2005-06-06 | 2006-12-14 | University Of South Florida | Treatment with sigma receptor agonists post-stroke |
| FR2970869B1 (fr) * | 2011-01-31 | 2013-09-06 | Centre Nat Rech Scient | Utilisation du recepteur sigma-1 pour reguler l'expression des canaux ioniques au niveau post-transcriptionnel |
| WO2016138135A1 (en) | 2015-02-25 | 2016-09-01 | Teva Pharmaceuticals International Gmbh | Sigma-1 receptor modulators for treating huntington's disease |
| RS62615B1 (sr) | 2016-02-11 | 2021-12-31 | Sigmathera Sas | Igmezin za upotrebu u lečenju alchajmerove bolesti |
-
2017
- 2017-02-10 RS RS20211350A patent/RS62615B1/sr unknown
- 2017-02-10 WO PCT/EP2017/053066 patent/WO2017137600A1/en active Application Filing
- 2017-02-10 PL PL17704271T patent/PL3413870T3/pl unknown
- 2017-02-10 LT LTEPPCT/EP2017/053066T patent/LT3413870T/lt unknown
- 2017-02-10 EP EP17704271.0A patent/EP3413870B1/en active Active
- 2017-02-10 JP JP2018543150A patent/JP7059192B2/ja active Active
- 2017-02-10 PT PT177042710T patent/PT3413870T/pt unknown
- 2017-02-10 AU AU2017218592A patent/AU2017218592B2/en active Active
- 2017-02-10 CN CN201780021077.9A patent/CN109069414B/zh active Active
- 2017-02-10 DK DK17704271.0T patent/DK3413870T3/da active
- 2017-02-10 US US16/076,504 patent/US11129801B2/en active Active
- 2017-02-10 CA CA3012415A patent/CA3012415C/en active Active
- 2017-02-10 EP EP21181531.1A patent/EP3903767A1/en active Pending
- 2017-02-10 HU HUE17704271A patent/HUE056265T2/hu unknown
- 2017-02-10 SI SI201730963T patent/SI3413870T1/sl unknown
- 2017-02-10 ES ES17704271T patent/ES2895957T3/es active Active
- 2017-02-10 HR HRP20211661TT patent/HRP20211661T1/hr unknown
-
2021
- 2021-10-26 CY CY20211100929T patent/CY1124821T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017218592A1 (en) | 2018-08-09 |
| US20190046472A1 (en) | 2019-02-14 |
| WO2017137600A1 (en) | 2017-08-17 |
| EP3413870A1 (en) | 2018-12-19 |
| ES2895957T3 (es) | 2022-02-23 |
| JP2019504872A (ja) | 2019-02-21 |
| CA3012415C (en) | 2024-03-12 |
| RS62615B1 (sr) | 2021-12-31 |
| US11129801B2 (en) | 2021-09-28 |
| HRP20211661T1 (hr) | 2022-02-18 |
| JP7059192B2 (ja) | 2022-04-25 |
| SI3413870T1 (sl) | 2021-12-31 |
| DK3413870T3 (da) | 2021-11-01 |
| CA3012415A1 (en) | 2017-08-17 |
| CN109069414B (zh) | 2022-01-14 |
| PL3413870T3 (pl) | 2022-01-10 |
| EP3413870B1 (en) | 2021-08-04 |
| LT3413870T (lt) | 2021-11-10 |
| CN109069414A (zh) | 2018-12-21 |
| EP3903767A1 (en) | 2021-11-03 |
| AU2017218592B2 (en) | 2022-10-20 |
| PT3413870T (pt) | 2021-09-10 |
| CY1124821T1 (el) | 2022-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL263433A (en) | Methods for treating Alzheimer's disease | |
| HUE063369T2 (hu) | Vegyületek Alzheimer-kór kezelésében történõ alkalmazásra APOE4+/+ betegekben | |
| SI3347002T1 (sl) | Zdravljenje Alzheimerjeve bolezni pri določeni populaciji bolnikov | |
| IL263188B (en) | Treatment for Parkinson's disease | |
| EP3377118A4 (en) | METHOD FOR THE TREATMENT OF MORBUS ALZHEIMER AND RELATED DISEASES | |
| IL264040A (en) | An oxazine derivative for use in the prevention of alzheimer's disease in at risk patients | |
| HK1243709A1 (zh) | 可用於治療阿爾茨海默氏病的四氫呋喃稠合的氨基氫噻嗪衍生物 | |
| PL3352742T3 (pl) | Kompozycje zawierające triterpenoidy do leczenia choroby alzheimera i choroby parkinsona | |
| SI3413870T1 (sl) | Igmezin za uporabo pri zdravljenju alzheimerjeve bolezni | |
| EP3162377A4 (en) | Use of -asarone in preparing drugs for preventing and treating alzheimer's disease | |
| IL265911A (en) | Epilimod preparations and methods of using them in the treatment of Alzheimer's disease | |
| ZA201808361B (en) | Benzoxazine or quinazoline derivatives for use in the treatment of alzheimer¿s disease | |
| ZA201801945B (en) | Compositions and methods for the treatment of parkinson's disease | |
| GB201710410D0 (en) | Inorganic polyphosphate formulations for use in the treatment of alzheimer disease | |
| ZA201807944B (en) | Treatment for parkinson's disease | |
| GB201800987D0 (en) | tHIRD alzheimer's treatment | |
| GB201800588D0 (en) | Third Alzheimer's Treatment | |
| GB201614863D0 (en) | Alzheimer's disease | |
| GB201511453D0 (en) | Treatment of alzheimer's disease | |
| GB201603510D0 (en) | Compositions for use in the treatment of neurological disease | |
| AU2015904411A0 (en) | Compositions and methods for the treatment of Alzheimer's disease | |
| SG11201607693WA (en) | 6-substituted estradiol derivatives for the treatment of alzheimer's disease |